Bioequivalence and Bioavailability Forum

Dear ElMaestro,

❝ At a general level I am not sure I realise when one would not specify "everything", despite the quote from Potvin's paper. Are you able to elaborate?

Sorry. To quote myself: "I'm not sure ...".
It was just a feeling resulting from what I have seen in meta-analyses where likewise often only a study effect is specified.

I think that one may run in trouble if the stage x treatment interaction comes out as statistical significant. If this is not just by chance IMHO this would mean that a pooling of the data from both stages is not appropriate because the treatments behave different between them.
But this is a case of a pre-test with all the bells and whistles of such a method ...

Moreover interactions are known in common to be hardly detectable as statistical significant. Then a parsimonious model would not specify them.

But as I said, it's just a feeling.